.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR14_DarunavirAndCobicistat.DarunavirAndCobicistat .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR14_DarunavirAndCobicistat.DarunavirAndCobicistat| name: | DarunavirAndCobicistat |
| ATC code: | J05AR14 | route: | oral |
| n-compartments | 1 |
Darunavir and cobicistat is a fixed-dose combination antiretroviral medication used primarily for the treatment of HIV-1 infection in adults and adolescents. Darunavir is a protease inhibitor while cobicistat acts as a pharmacokinetic enhancer (booster) by inhibiting CYP3A-mediated metabolism, increasing serum concentrations of darunavir. This combination is approved for clinical use.
Pharmacokinetic parameters reported in healthy adult volunteers and HIV-infected patients; generally studied after oral administration of a fixed-dose tablet containing 800 mg darunavir and 150 mg cobicistat once daily.